Sumitomo Mitsui Trust Group Inc. Has $181.02 Million Stock Position in Ventas, Inc. $VTR

Sumitomo Mitsui Trust Group Inc. increased its stake in Ventas, Inc. (NYSE:VTR) by 74.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,586,405 shares of the real estate investment trust’s stock after purchasing an additional 1,101,948 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.57% of Ventas worth $181,022,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in Ventas in the 2nd quarter valued at about $344,740,000. Vanguard Group Inc. boosted its position in shares of Ventas by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 71,796,312 shares of the real estate investment trust’s stock worth $4,533,937,000 after acquiring an additional 2,854,751 shares in the last quarter. Citigroup Inc. increased its stake in Ventas by 451.9% in the second quarter. Citigroup Inc. now owns 2,316,344 shares of the real estate investment trust’s stock valued at $146,277,000 after acquiring an additional 1,896,627 shares during the last quarter. State Street Corp raised its position in Ventas by 5.2% during the second quarter. State Street Corp now owns 27,998,629 shares of the real estate investment trust’s stock valued at $1,781,267,000 after purchasing an additional 1,388,678 shares in the last quarter. Finally, Invesco Ltd. raised its position in Ventas by 36.1% during the second quarter. Invesco Ltd. now owns 4,812,970 shares of the real estate investment trust’s stock valued at $303,939,000 after purchasing an additional 1,275,446 shares in the last quarter. Institutional investors own 94.18% of the company’s stock.

Ventas Stock Performance

Shares of VTR stock opened at $75.61 on Tuesday. The business’s 50-day moving average price is $78.28 and its 200-day moving average price is $71.51. Ventas, Inc. has a 12 month low of $56.97 and a 12 month high of $81.89. The company has a current ratio of 0.32, a quick ratio of 0.32 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $35.52 billion, a price-to-earnings ratio of 145.41, a PEG ratio of 1.85 and a beta of 0.78.

Ventas (NYSE:VTR) last issued its quarterly earnings data on Wednesday, October 29th. The real estate investment trust reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.01. Ventas had a net margin of 4.28% and a return on equity of 2.05%. The business had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same quarter last year, the business earned $0.80 EPS. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. Ventas has set its FY 2025 guidance at 3.450-3.480 EPS. Equities research analysts forecast that Ventas, Inc. will post 3.4 EPS for the current year.

Ventas Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Wednesday, December 31st will be issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, December 31st. Ventas’s dividend payout ratio is presently 369.23%.

Insider Buying and Selling

In other Ventas news, CFO Robert F. Probst sold 33,591 shares of Ventas stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $76.77, for a total transaction of $2,578,781.07. Following the transaction, the chief financial officer directly owned 168,364 shares of the company’s stock, valued at approximately $12,925,304.28. The trade was a 16.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Debra A. Cafaro sold 317,258 shares of the company’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $74.24, for a total value of $23,553,233.92. Following the completion of the sale, the chief executive officer owned 1,145,695 shares in the company, valued at $85,056,396.80. This trade represents a 21.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 713,520 shares of company stock valued at $52,788,577 in the last three months. Insiders own 1.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on VTR shares. Scotiabank lifted their price target on Ventas from $74.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, November 13th. Evercore ISI raised their price objective on Ventas from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, September 15th. UBS Group started coverage on Ventas in a research report on Friday, September 19th. They issued a “neutral” rating and a $73.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Ventas in a report on Friday. They issued a “buy” rating and a $94.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $93.00 price target on shares of Ventas in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Ventas currently has an average rating of “Moderate Buy” and a consensus price target of $80.65.

Ventas Company Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.